N
NextCure, Inc. (NXTC)
NMS – Real vaqt narxi. Valyuta: USD
1.65
-0.01 (-0.30%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.64
-0.00 (-0.30%)
Bozordan keyin: Jun 26, 2026, 7:55 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
1.65
-0.01 (-0.30%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.64
-0.00 (-0.30%)
Bozordan keyin: Jun 26, 2026, 7:55 PM EDT
NextCure, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saratonni davolash uchun dori vositalarini ishlab chiqish bilan shug'ullanadi. Kompaniyaning mahsulot nomzodi LNCB74 bo'lib, bu B7-H4 ga yo'naltirilgan ADC bo'lib, u o'smalarni yo'q qilish uchun mo'ljallangan. Kompaniya, shuningdek, LAIR-1 orqali immunitetni bostirishni bloklash uchun mo'ljallangan LAIR-2 ning birlashgan oqsili NC410; o'tkir miyeloid leykemiya, blast hujayralari va leykemik ildiz hujayralariga yo'naltirilgan yangi LAIR-1 antitelasi NC525; Altsgeymer kasalligini davolash uchun ApoE4 ga yo'naltirilgan insonlashtirilgan antitelasi NC181; va Siglec-15 ga, shuningdek, osteoartrit va birikmaydigan sinishlar kabi surunkali suyak kasalliklariga yo'naltirilgan antitelasi NC605 ni ishlab chiqadi. Kompaniya, shuningdek, qattiq o'smalarni davolash uchun CDH6 (kadherin-6 yoki K-kadherin) ga yo'naltirilgan yangi antitel-dori konjugati (ADC) SIM0505 ni ishlab chiqadi. Kompaniya 2015 yilda ro'yxatga olingan va shtab-kvartirasi Beltsville, Merilendda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Sebastien Maloveste Ph.D. | Senior Vice President of Business Development |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer |
| Dr. Udayan Guha M.D., Ph.D. | Chief Medical Officer |
| Mr. Kevin G. Shaw | Senior VP & General Counsel |
| Mr. Michael S. Richman MSBA | Co-Founder, CEO, President & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-25 | 8-K | nxtc-20260618x8k.htm |
| 2026-06-01 | 8-K | nxtc-20260601x8k.htm |
| 2026-05-07 | 10-Q | nxtc-20260331x10q.htm |
| 2026-04-24 | DEFA14A | tm261451d5_defa14a.htm |
| 2026-04-24 | DEF 14A | tm261451-3_def14a.htm |
| 2026-03-05 | 8-K | nxtc-20260305x8k.htm |
| 2026-03-05 | 10-K | nxtc-20251231x10k.htm |
| 2026-01-23 | 8-K | nxtc-20260123x8k.htm |
| 2025-12-19 | 8-K | tm2533962d1_8k.htm |
| 2025-12-10 | D |
| Mr. Sourav Kundu Ph.D. | Senior Vice President of Development & Manufacturing |
| Mr. Steven P. Cobourn CPA | Chief Financial Officer |